Ebos Group Limited

Overview

Formerly Early Bros Dental & Surgical Supplies Ltd, the company's business was restructured in the 1990s. The major focus now is the marketing of medical consumable products, and growth has been assisted by acquisitions on both sides of the Tasman since 1996. These included Richard Thomson & Co, Health Support Ltd, Maygar Medical, Medic Corporation, Nature's Kiss creams and the Australian Allersearch range of asthma products.

In October 2002 it announced a joint venture of its former Medic Scientific division with Global Science, giving EBO 47.5% of the new entity. In 2004, the company acquired healthcare product distributor Vernon-Carus and the Melbourne based company, Stelmara Medical.

In January 2005 it increased its stake in Global Science from 47.5% to 67% and in March that year acquired the Australian business of Quantum Scientific. In December 2005 it raised its shareholding in Global Science to 100%. Global Science also acquired 100% of Scientific Supplies Ltd - a NZ-based specialty supplier of chemicals to the scientific market.

In August 2007, it acquired pharmaceuticals distributor PRNZ for $86.3m in cash and shares. In July 2008 it acquired MedBio Scientific.

In April 2009, EBO entered into a new issuance and share buyback as part of its profit distribution plan. Under the Profit Distribution Plan shareholders can elect to have the company buy back shares issued to them under the Plan at the issue price of $4.691798 per share.

As a result of shareholder elections the company achieved an off-market buy back of 279,875 shares. Of the total number of bonus shares issued in respect of the 2009 interim profit distribution (of 10.5 cps), 74.1% of shares are being retained with 25.9% electing the buyback option.

The company has elected to cancel all of the 279,875 shares bought back. With the issue of 1,080,305 new shares and the cancellation of 279,875 shares bought back, the total number of shares on issue is now 48,980,799.

On 14 June 2013, shareholders elected to proceed with a pro-rata renounceable Entitlement Offer of 7 new ordinary shares for every 20 existing ordinary shares held on the Record Date. The transaction settlement is expected to take place on or about 5 July 2013.

In November 2015, the company acquired Red Seal, a leading New Zealand natural health product business, for NZ$80 million.

Performance

The following information was extracted from EBOS Group Limited's full year results, released on 19 August 2026:

EBOS Group Limited (“EBOS or the Group”) today reports its full year results to 30 June 2026 (FY26) delivering strong revenue growth of 9.9% to $13.5 billion and Underlying EBITDA growth of 5.0% to $614 million. The result was supported by broad-based growth across Healthcare and Animal Care, together with contributions from recent acquisitions, and was achieved despite elevated fuel costs and foreign exchange headwinds. All FY26 financial guidance metrics were delivered within the Group's stated ranges.

The result marks an important milestone for the Group, with EBOS completing its four-year, $360 million distribution centre renewal program. All major facilities are now operational, with the Group focused on optimisation and driving utilisation, productivity and growth, supporting stronger free cash flow generation and improving return on capital.

Financial highlights

• Revenue increased 9.9% to $13.5 billion

• Gross operating revenue (GOR) increased 6.5% to $1.7 billion

• Underlying EBITDA increased 5.0% to $614 million

• Underlying NPAT was $250 million, down 3.1%, reflecting higher depreciation & amortisation and financing costs associated with the Group’s investment cycle

• Statutory NPAT was $225 million, up 4.7%

• Leverage was 2.1x, remaining within the Group’s target range of 1.7x to 2.3x

• ROCE was 12.8%, down 20bps, reflecting the higher capital base

• Final dividend maintained at NZ 61.5 cents per share, with a payout ratio of 84.5% of Underlying NPAT